Determination of valproic acid dose level and influence of enzyme-inducing and non-enzyme-inducing drugs in volunteer patients of the city of Mérida, Venezuela
DOI:
https://doi.org/10.24265/horizmed.2017.v17n3.06Keywords:
Level/dose ratio (ND), Valproic acid, Enzyme-inducing drugs, Non-enzyme-inducing drugsAbstract
Objective: To determine valproic acid level/dose ratio (ND) and the influence of enzyme-inducing and non-enzymeinducing drugs in volunteer patients of the city of Mérida, Venezuela. Materials and methods: An experimental, observational, prospective, cross-sectional study was conducted at the Hospital de Mérida, Venezuela. After undergoing the inclusion and exclusion criteria process, patients signed an informed consent individually and voluntarily. The protocol consisted in collecting blood from 88 patients (42 males y 46 females) from 16 to 68 years old, who had partial or generalized seizures, and were receiving 3.97-38.04 mg/kg of valproic acid (AVP) twice a day as monotherapy or combination therapy with carbamazepine (CBZ), phenobarbital (PB), phenytoin (PHT), lamotrigine (LTG) and oxcarbazepine (OXC). A sample was taken after four weeks of treatment, in the fasting state and before the administration of the medication of the day. Afterwards, plasma concentration was determined through a radioimmunoassay method. The ND was established using the plasma concentration data. Results: AVP monotherapy showed a mean plasma concentration of 64.94 mg/l (SD 31.7) and ND of 4.32 (SD 2.1). Combination therapy with AVP+CBZ+PB showed an ND of 2.31 (SD 0.06), combination therapy with AVP+PB+PHT showed an ND of 2.46 (SD 0.43) and combination therapy with AVP+PB+OXC showed an ND of 4.63 (SD 3.12). Conclusions: The administration of concomitant drugs affected plasma concentration and AVP ND in a group of patients of the Hospital de Mérida, Venezuela.
Downloads
References
Bravo S, Caminos J, Eslava J. Medicina personalizada: farmacogenómica y farmacoepigenética. Rev Col Anestesiología. 2011; 39(3):308-13.
Medrano A. Medicina personalizada: hacia un nuevo modelo en la práctica médica. Arch Neurocien (Mex). 2012; 17(2):129-31.
Precision Medicine Initiative (PMI) Working Group Report to the Advisory Committee to the Director, NIH. The Precision Medicine Initiative Cohort Program-Building a Research Foundation for 21st Century Medicine. Estados Unidos, 2015.
Garassino M. Medicina personalizada para el cáncer: Una guía ESMO para los pacientes. Sociedad Europea de Oncología Médica. [Internet]. 2013 [citado 25 de abril de 2017]. Recuperadp a partir de: https://www.esmo.org/content/download/46499/855050/file/ESMO-Medicina-Personalizada-Guia-para-Pacientes.pdf
Alvarado A, Salazar A, Pineda N, Villanueva H, Cáceres E. Estudio de la biodisponibilidad relativa de una formulación multifuente de sulfametoxazol respecto al medicamento referente. Horiz Med. 2016;16 (3):12-9.
Alvarado A, Lozada G, Llerena R, Macavilca S, Marcos E, Pisconte N, Poma J, Ismodes Y. Determinación del margen terapéutico y estudio de la equivalencia biofarmacéutica de las tabletas multifuentes de digoxina de 0,25 mg. Horiz Med. 2014;14 (4): 48-52.
Fernández E, Serrano D, Villamarín L. Monitorización clínica de medicamentos. Butlletí d´informació Terapéutica 2011;22(9):51-5.
RET. Farmacología básica del valproato. Revista de Toxicomanías. [Internet]. 2006 [citado 25 de abril de 2017];47:11-33. Recuperadp a partir de: http://www.catbarcelona.com/uploads/rets/47_2.pdf
Gamez G, Zhu L, Disko A, Chen H, Azov V, Chingin K, et al. Real-time, in vivo monitoring and pharmacokinetics of valproic acid via a novel biomarker in exhaled breathw. Chem. Commun. 2011;47: 4884-6.
Salas-Puig J. Farmacología del valproato sódico. Emergencias. 2005;17:79-82.
Dutta S, Zhang Y, Lee L, O’Dea R. Comparison of the Bioavailability of 250 and 500mg Divalproex Sodium Extended- Release Tablets in Healthy Volunteers. Biopharm. Drug Dispos. 2004;25(8): 353-7.
Dulac O, Alvarez JC. Bioequivalence of a New Sustained- Release Formulation of Sodium Valproate, Valproate Modified- Release Granules, Compared with Existing Sustained-Release Formulations After Once- or Twice-Daily Administration. Pharmacotherapy. 2005;25(1):35-41.
Lorenzo P, Moreno A, Leza J, Lizasoain I, Moro M. Velásquez Farmacología Básica y Clínica. Madrid. 17 ed. Mexico. Panamericana; 2005.
Lana F, Marti-Bonany J, Fuster J, de León J. Reduction in serum concentration of valproic acid secondary to the intake of ibuprofen as an example of valproico acid auto-induction metabolism. Actas Esp Psiquiatr. 2016;44(4):136-44.
Fujisaki Y, Tsukune T, Funyû M, Okumura M, Ukigaya T, Sugibayashi K. Development of Sustained-ReleaseTablets Containing Sodium Valproate: In Vitro and In Vivo Correlation. Drug Development and Industrial Pharmacy. 2006;32(2) :207-17.
Aldaz A, Ferriols R, Aumente D, Calvo MV, Farre MR, García B, et al. Monitorización farmacocinética de antiepilépticos. Farm Hosp. 2011;35(6):326-39.
Sabin O, Pop R, Trifa A, Buzoianu A. The influence of CYP2C9, CYP2C19 and ABCB1 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Human y Veterinary Medicine International Journal of the Bioflux Society. 2016;8(1):29-33.
Komatsu T, Yamazaki H, Asahi S, Gillam E, Guengerich F, Nakajima M, et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes cytosol: roles of cytochromes P450 2C9, 2C19, and 3A4. Drug Metab Dispos. 2000;28(11):1361-9.
Saldaña A, Sánchez J, Márquez D, García A, Flores S. Farmacogenética y metabolismo de fármacos antiepilépticos: implicación de variantes genéticas en citocromos P450. Rev Neurol. 2013; 56 (9):471-9.
Ghodke Y, Thorn C, Lamba J, Leeder J, Song W, Birnbaum A, et al. Valproic acid pathway: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2013;23(4): 236-41.
Zhao M, Li G, Qiu F, Sun Y, Xu Y, et al. Development and Validation of a Simple and Rapid UPLC–MS Assay for Valproic Acid and Its Comparison With Immunoassay and HPLC Methods. Ther Drug Monit. 2016; 38 (2):246-52.
Hermida J, Tutor J. A Theoretical Method for Normalizing Total Serum Valproic Acid Concentration in Hypoalbuminemic Patients. Journal of Pharmacological Sciences. 2005;97(4): 489-93.
Adín J, Cruz M, Blanco Y, Herranz J, Armijo J. Topiramate Serum Concentration-to-Dose Ratio:Influence of Age and Concomitant Antiepileptic Drugs and Monitoring Implications. Ther Drug Monit. 2004;26(3):251–7.
Büdi T, Tóth K, Nagy A, Szever Z, Kiss A, Temesvári M, et al. Clinical significance of CYP2C9-status guided valproic acid therapy in children. Epilepsia. 2015:56(6):849–55.
Nakashima H, Oniki K, Nishimura M, Ogusu N, Shimomasuda M, Ono T, et al. Determination of the Optimal Concentration of Valproic Acid in Patients with Epilepsy: A Population Pharmacokinetic-Pharmacodynamic Analysis. Plos one. 2015:10(10); 1-14.
Lin W, Jiao Z, Wang Ch, Wang H, Ma Ch, Huang P, et al. Population Pharmacokinetics of Valproic Acid in Adult Chinese Epileptic Patients and its Application in an Individualized Dosage Regimen. Ther Drug Monit. 2015;37(1):76–83.
May T, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine.Clin Pharmacokinet. 2003;42(12):1023-65.
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Juan Camilo Cotuá Urzola, Alexis Morales Ortiz, Maryori Delgado Nilo, Ana María Muñoz Jáuregui, Luis Quiñones Sepúlveda, Alberto Salazar-Granara, Ángel Alvarado-Yarasca
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
